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Abstract
Introduction and hypothesis Intravesical onabotulinumtoxinA
(Botox) injections are effective for the treatment of idiopathic
overactive bladder (OAB) symptoms. The aim of our study
was to assess the predisposing factors for urinary retention in
women with OAB after intravesical Botox injection.
Methods All participants were women of European descent
with idiopathic OAB. OnabotulinumtoxinA (100 U) was ad-
ministered in 20 intra-detrusor injections. Analysis was per-
formed based on the results of safety assessments made during
follow-up (FU) visits on weeks 2, 4 and 12, in 208 women
who were treated with Botox injections for refractory OAB
and who completed all FU visits.
Results Women who required clean intermittent self-
catheterisation (CISC) and those with post-void residual
(PVR) greater than 200 ml were older in comparison with
patients with PVR between 50 and 200 ml. Patients who re-
quired CISC were also characterised by higher parity and
particularly by a higher number of vaginal deliveries. Other
factors such as body mass index or comorbidities did not
significantly influence PVR and the risk of CISC.
Conclusions Elderly and/or multiparous women are at in-
creased risk of urinary retention after intravesical 100-U
Botox injections. The risk of new onset urine retention in
our study has completely disappeared 2 weeks after Botox
injections. Based on our results of the way in which the
PVRs have changed over time, we can conclude that OAB
patients should be optimally assessed during the first 2 weeks
after Botox injections.
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Introduction
An International Urogynecological Association (IUGA) and
International Continence Society (ICS) joint report on the ter-
minology for female pelvic floor dysfunction have defined
overactive bladder (OAB) syndrome as urinary urgency, usu-
ally accompanied by frequency and nocturia, with or without
urgency urinary incontinence, in the absence of urinary tract
infection or other obvious pathological condition [1]. The
prevalence of OAB in the population is over 16 % and it
increases with age [2]. Moreover, symptoms of OAB affect
more than 30 % of elderly patients [3]. Following behavioural
therapy anticholinergic agents and/or mirabegron are then the
mainstay of pharmacological treatment of OAB. However, in
non-responders who are inadequately managed with such oral
therapies there is a need for the intravesical injections of
onabotulinumtoxinA (Botox) [4]. The National Institute for
Health and Care Excellence (NICE) guidelines highlight that
before invasive treatments, which include intravesical botuli-
num toxin injections, women with refractory OAB should
undergo a multidisciplinary team review to ensure that all
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other non-invasive treatment options have been exhausted [5].
Adverse effects including the potential risk of urinary reten-
tion requiring catheterisation are among the greatest concerns
for OAB patients considering Botox injections [6].
The efficacy of Botox (100 U; Allergan, Dublin, Ireland) in
the treatment of idiopathic OAB has been proven in several
randomised clinical trials; however, the risk factors for the oc-
currence of urinary retention after Botox injections are still not
well recognised [7–10]. One multicentre, placebo-controlled,
dose-ranging study (doses of 50 to 300 U) reported a dose-
dependent proportion of patients with a post-treatment post-
void residual (PVR) of 200 ml or greater. In patients who were
treated at a dose of 100 U the percentage of clean intermittent
self-catheterisation (CISC) was 10.9 %, whereas in the group
treated with 200 U, the rate was almost double (21.2 %) [10].
The results of a long-term extension study, which included
female and male patients, has found that the rate of de novo
CISC was 4.0 % after the first Botox (100 U) injection cycle.
Interestingly, patients who do not need to self-catheterise after
their first Botox treatment are at a lower risk of needing CISC in
later treatment cycles. The rate of CISC due to urinary retention
was <2.0 % in all subsequent re-injection cycles [7]. One previ-
ous study has confirmed the association between increased pre-
operative PVR with urine retention after Botox injections [11].
The results of randomised clinical trials (RCTs) and non-
randomised observational studies do not describe the factors
for the prediction of urine retention after Botox (100U) injec-
tions in patients with refractory OAB very well [8–11]. The
possibility of forecasting the risk of urinary retention after
Botox injections could facilitate shared decision-making for
third-line treatment options for refractory OAB. The aim of
our observational study was to assess the predisposing factors
for urinary retention in OAB women after intravesical Botox
(100 U) injections.
Materials and methods
The study protocol was approved by the local ethics commit-
tee. All participants were women of European descent. From
February 2009 to November 2015, a total of 252 patients with
refractory OAB were included in this prospective study.
Analysis was performed based on the results of safety assess-
ments made during follow-up (FU) visits on weeks 2, 4, 12
and at any other time in patients with clinically relevant uri-
nary retention depending on need, in 208 women who were
treated with Botox injections and who completed all FU visits.
Patients were informed about potential adverse events of
Botox and written consent was obtained from all study partic-
ipants. Inclusion and exclusion criteria are summarised in
Table 1. Patients were qualified for the treatment based on
the results of 3-day bladder diaries.
Two percent lidocaine solution was infused into the bladder
for at least 20 min before each procedure. Botox was admin-
istered by one of three investigators, dissolved into 10 ml of
0.9 % saline chloride and given in trigone-sparing injections
in 20 sites during rigid cystoscopy under local anaesthesia.
PVR measurements were checked with a single, three-dimen-
sional, abdominal ultrasound in all patients before each pro-
cedure and at each follow-up visit. Urine dipstick testing was
performed to screen for urinary tract infection (UTI). For pa-
tients with positive urinalysis, urine cultures were performed,
and treatment of presumptive UTI was implemented. The pa-
tients were separated into five subgroups based on the results
of PVR (residual urine volume: < 50 ml; 51–100 ml; 101–
200 ml; 201–350 ml; urine retention requiring CISC) assessed
at week 2 of follow-up. The incidence and severity of urine
retention after Botox injections were assessed by two blinded
evaluators. All patients with PVR greater than 350 ml were
advised to start CISC. Patients with PVR <350 ml with sig-
nificant symptoms of incomplete bladder emptying or voiding
difficulties were also advised to perform CISC. Patients who
performed CISC were checked using abdominal ultrasound in
the out-patient clinic every 7–10 days. Moreover, the kidney
scans were performed in all patients with urine retention be-
cause of the risk of upper urinary tract dilation and renal in-
sufficiency. Patients on CISC took oral prophylaxis (furagin
or ciprofloxacin) to prevent urinary tract infection. CISC was
stopped when the patient had no clinical symptoms and PVR
as measured by ultrasound was less than 300 ml.
The primary outcome measures included urinary retention,
defined as the necessity for CISC, and PVR volumes after
Botox injections. All associated factors (age, BMI, parity, co-
morbidities), which could potentially influence primary out-
comes, were assessed using multivariate logistic regression
tests. The secondary outcomes measure includes the duration
of CISC and its association with potential risk factors for
CISC. Statistical analysis was performed using Statistica
Statsoft, version 12 package, with the Chi-squared test,
ANOVAwith post-hoc tests and Student’s t test, as appropri-
ate. A p value < 0.05 was considered statistically significant.
Results
The average age of women with OAB who completed the
study (n = 208) was 61.2 ± 13.4 years and 68.2 % (n = 142)
were postmenopausal. Before treatment, women with OAB
reported: 11.2 (±1.7) micturitions/24 h, 1.75 (±0.74) UUI/
24 h and 220.7 (±28.9) ml voided volume. The mean value
of the body mass index (BMI) was 29.5 ± 5.0 (kg/m2) and the
mean value for parity was 2.48 ± 1.26. Thirty-six participants
(17.3 %) had undergone hysterectomy (30 abdominal and 6
vaginal) in the past. Women in our study group had pelvic
organ prolapse (POP) stage 0 (n = 78, 37.5 %) and stage 1
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(n = 130, 62.5%) [12]. All patients, after three ormore vaginal
deliveries, had POP stage 1. However, the statistical analyses
did not show the significant influence of POP stage on the PVR
after treatment in our group. We performed uroflowmetry at the
baseline and checked PVR to identify patients with bladder
outlet obstruction and/or hypoactive bladder. The mean value
of the maximum flow in our study was 26.2 ml/s (±8.9). We
observed a moderate but statistically significant negative corre-
lation between age and maximum flow (r = −0.39; p < 0.001).
Common comorbidities, such as hypertension, diabetes
and asthma were observed in 58.6, 15.3 and 7.7 % of partic-
ipants respectively. PVR volumes are summarised in Table 2.
Patients were instructed how to perform CISC before the pro-
cedure; however, all women with urinary retention were re-
instructed, if needed, before starting CISC. In the CISC group
2 patients demonstrated clinically significant voiding dysfunc-
tion (5 and 10 days after Botox injection) and they were un-
able to void spontaneously; PVRs in these patients were 250
and 290 ml respectively. Moreover, 11 patients in the CISC
group demonstrated PVR greater than 350 ml at week 2. Ten
of them reported noticeable voiding symptoms (splitting, hes-
itancy, terminal dribbling) during spontaneous micturition
and/or post-micturition feeling of incomplete bladder empty-
ing, and 1 patient demonstrated PVR > 500 ml without signif-
icant voiding symptoms.
Womenwho requiredCISC and thosewith PVR greater than
200 ml were older in comparison with patients with PVR be-
tween 50 and 200ml. Interestingly, patients who required CISC
were also characterised by higher parity and a higher number of
vaginal deliveries (Table 3). Multivariate logistic regression
analysis demonstrated that three or more vaginal deliveries no-
ticeably increased the risk of CISC (odds ratio [OR] 6.86, 95 %
confidence interval [CI] 1.76–26.9, p < 0.01). Other factors,
such as body mass index or comorbidities did not significantly
influence PVR volumes and the risk of CISC. None of the
patients required CICS at week 12 (Table 2). The minimum
duration of CISC in our study group was 20 days and a maxi-
mum of 83 days with a mean of 45.5 days. We did not find a
statistically significant association between any potential risk
factors and the duration of CISC.
Table 1 Inclusion and exclusion
criteria of the study Inclusion criteria Exclusion criteria
Non-pregnant women over 18 years of age Previous onabotulinumtoxinA injections to treat
urological conditions
Idiopathic overactive bladder wet symptoms: Contraindications to onabotulinumtoxinA use
≥8 micturitions/24 h Contraindications to clean intermittent
self-catheterisation
≥1 urgency urinary incontinence/24 h Allergy to lidocaine
Lack of efficacy (at least two drugs, each for ≥1 month)
or intolerance of antimuscarinic therapy and/or lack
of efficacy or intolerance of mirabegron (≥1 month)
Previous anti-incontinence or prolapse surgery
Stage 0 or 1 on pelvic organ prolapse quantification
(POP-Q) scale
Stress or mixed urinary incontinence
Maximum flow (Q-max) on uroflowmetry > 15 ml/s Painful bladder syndrome
Atrophic vaginitis
Urinary tract infection
Bladder or pelvic tumours and/or stones
Neurological disorders affecting bladder function
Post-void residual >100 ml before treatment
Uncontrolled systemic disease, i.e. diabetes
Stage > 2 on the POP-Q scale
Table 2 Residual volumes after








Residual urine volume < 50 ml 106 (50.9) 115 (55.2) 188 (90.3)
Residual urine volume 51−100 ml 41 (19.7) 52 (25) 15 (7.2)
Residual urine volume 101–200 ml 35 (16.8) 28 (13.4) 4 (1.9)
Residual urine volume 201−350 ml 13 (6.2) 4 (1.9) 1 (0.4)
Urine retention requiring CISC 13 (6.2) 9 (4.3) 0
CISC- clean intermittent self-catheterisation
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Discussion
A recent online survey asked participants with OAB about
their preferences for more invasive treatment options.
Participants were informed about all the potential benefits
and risks of sacral neuromodulation (SNM), Botox injections
and percutaneous tibial nerve stimulation (PTNS). Among
127 patients who had only experience with oral medications
(anticholinergics or mirabegron) the most preferred option
was PTNS (56.7 %), followed by SNM (34 %) and Botox
injections (9.4 %) [13]. However, in another similar study,
74 % of women with OAB chose Botox treatment and 26 %
chose SNM after failed anticholinergic treatment. Over 46 %
of patients in the SNM group chose SNM to avoid the risk of
urinary retention after Botox injections [14].
Patients with pelvic organ prolapse (POP) stage greater
than 1 were excluded from the study. The increased prolapse
stage may be a physical cause of the voiding dysfunction. It
has already been published that the finding of an elevated
PVR was significantly more common in patients with POP
stage 2 or greater than in patients with stage 2 or less. The
presence of an elevated PVRwas significantly associated with
symptoms of voiding difficulty and symptoms of pelvic organ
prolapse. Moreover, increasing patient age was found to be a
predictor of an elevated PVR only through its association with
the presence of more advanced stages of POP (at least POP
stage 2). The finding of an elevated PVR was found to be
significantly more common in patients with POP stage 2 or
greater than in patients with POP stage 1 or less [15]. On
multivariate analysis the following independent predictors of
raised PVR were identified: age > 55 years (OR 3.71),
previous incontinence surgery (OR 4.32), a history of multiple
sclerosis (OR 15.32) and pelvic organ prolapse grade 2 or
greater (OR 3.61) [16]. Based on these results we did not
include patients with POP stage greater than 1 to avoid the
potential influence of pelvic organ prolapse on the post-
treatment PVR.
Urinary retention is one of the most severe adverse events
observed in OAB patients after Botox injections. Criteria for
significant retention remain contentious. It has been proposed
that PVR < 50 ml represents optimal emptying; therefore, we
used this criterion as a basis in our post-treatment observations
[17]. Moreover, a PVR > 200 ml clearly represents inadequate
emptying [17, 18]. A previous study revealed that in 95 % of
women aged <65 with a degree of pelvic organ prolapse ≤1
the PVR was less than 100 ml and this can be considered
normal [19]. In our study we decided to compare the potential
risk factors in patients with post-treatment values of PVR
greater than 100 ml (101–200 ml, 201–350 ml and required
CISC) with values below 50 and 100 ml. Over 6 % of patients
in our study required CISC owing to urinary retention after the
procedure. The rate of CISC after treatment with Botox
(100 U) ranged in published studies from 2 to 31.8 % and it
was associated with the patient population and the cycle of
treatment [7, 11]. A meta-analysis of efficacy and adverse
events after Botox trigonal vs extratrigonal injections revealed
that trigonal injections were more often associated with acute
urinary retention; however, this correlation was non-signifi-
cant. Moreover, trigonal injections led to non-significantly
higher values of PVR [20]. In a recently published series pa-
tients withOAB (wet or dry) were treatedwith 200 U of Botox
and were advised to commence CISC in all cases with PVR >
Table 3 The influence of
patients’ age and route of delivery
on the residual volumes at week 2
after Botox injections





(number), mean ± SD
Caesarean sections
















68.5 ± 10.2a 2.4 ± 1.8 2.2 ± 1.8 0.1 ± 0.3
Group 5
urine retention requiring
CISC (n = 13)
68.8 ± 11.2b 3.4 ± 1.3c 3.2 ± 1.0c 0.0
a Group 4 vs group 2 (p < 0.01) and group 4 vs group 3 (p < 0.05)
b Group 5 vs group 2 (p < 0.01) and group 5 vs group 3 (p < 0.05)
c Group 5 vs other groups (p < 0.01)
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150 ml. This strict recommendation may have been associated
with the higher rates of CISC observed in this study: 23 % of
all patients performed CISC. Moreover, high rates of CISC
could also be associated with the 200-U dose of Botox [21]. In
our study group all patients with increased PVRs who required
CISC were observed during the follow-up visit at week 2.
However, we had previously published that new onset urine
retention could develop as late as 2 weeks after the Botox in-
jections [22]. Therefore, patients should be informed about the
potential risk of postoperative urinary retention, which can be
observed even after an observation period of longer than
14 days. The mean duration of CISC in our study was 45 days
andwewere unable to determine factors that could significantly
influence this period. Nitti et al. reported that after the first
treatment cycle the median duration of CISC was 8.3 weeks
and it decreased to 4.8 and then 3.1 weeks after the second and
third Botox re-injections respectively [7]. Interestingly, in a pre-
vious RCT the longest reported period of CISC after treatment
with Botox (100 U) was 441 days [10].
We did not observe any influence of coexisting comorbid-
ities on the clinically important PVR after treatment, or on the
risk of CISC. In another age-matched controlled study it was
noted that patients with diabetes had a significantly increased
(p = 0.007) incidence of PVR > 150 ml (60.4 %) vs non-
diabetic patients (33.3 %) [23].
We found an increased risk of PVR (>200 ml) or CISC at
week 2 of follow-up in patients older than 68 years. In a
previous study it has been demonstrated that patients older
than 61 years had a higher incidence (35.6 %) of PVR >
200 ml at week 4 after treatment. Increased PVR after treat-
ment was also observed in patients older than 76 years
(29.0 %) [24]. This observation is consistent with previous
reports, which showed that elderly patients are more vulnera-
ble to complications and adverse events. Liao and Kuo inves-
tigated the efficacy and safety of intravesical Botox treatment
(100 U) in elderly (frail or not frail) in comparison with pa-
tients under the age of 65 years. Higher PVR urine volumes
(defined as greater than 150 ml) after a procedure were signif-
icantly more often seen in the frail elderly group than in the
other groups (60.7 % vs 39.7 and 35.7 % respectively, p =
0.018). Moreover, urinary retention was observed in 7 frail
elderly patients (11.5 %) and in 4 (6.3 %) elderly participants
who were not frail [25].
A high number of vaginal deliveries (VDs) was a signifi-
cant risk factor for CISC in our study group. We did not find
any previous studies that had investigated the influence of VD
on complications after Botox treatment. However, it has been
reported that vaginal childbirth is probably the most important
factor in the aetiology of pelvic floor dysfunction, either ana-
tomical or functional [26]. Therefore, it can be speculated that
a high number of VDs could significantly affect bladder func-
tion and could potentially have an influence on the effect of
pharmacological treatment.
The strengths of the study include the prospective design,
the homogeneous sample, and the highly pragmatic setting.
Moreover, the changes in CISC and duration of CISC were
reported between follow-up visits. The resulting findings
should have an immediate clinical impact in identifying pa-
tients with a potentially increased risk of urine retention after
intravesical Botox injection, enabling targeted third-line treat-
ment for women with OAB. Limitations of this study include
the lack of a placebo control group and the lack of
generalisability to male patients. In our opinion, the first
2 weeks after Botox injections are crucial for the observation
of PVR and voiding symptoms. Therefore, patients should be
informed that they could expect these adverse events relative-
ly early in the post-injection period. The risk of new onset
urine retention in our study has completely disappeared
2 weeks after Botox injections. Based on our results of the
way in which the PVRs have changed in time, we can con-
clude that OAB patients should be optimally assessed during
the first 2 weeks after Botox injections.
Elderly women and multiparous women are at an increased
risk of urinary retention after 100-U intravesical Botox injec-
tions. However, all patients, independent of age or parity,
should be warned before receiving Botox injections about
the potential risk of urine retention after treatment. The deci-
sion to instigate CISC should be made based on patients’
subjective significant voiding dysfunction symptoms
coexisting with increased PVR (<350 ml) or on the significant
increase in PVR measurements (>350 ml).
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